Prospective Safety Study of Intrathecal Gadobutrol in Different Doses

References

1. 1.↵
   1. Iliff JJ,
   2. Wang M,
   3. Liao Y, et al

   . A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β. Sci Transl Med 2012;4:147ra111 doi:10.1126/scitranslmed.3003748 pmid:22896675

   CrossRefPubMed
2. 2.↵
   1. Ringstad G,
   2. Vatnehol SA,
   3. Eide PK

   . Glymphatic MRI in idiopathic normal pressure hydrocephalus. Brain 2017;140:2691–705 doi:10.1093/brain/awx191 pmid:28969373

   CrossRefPubMed
3. 3.↵
   1. Ringstad G,
   2. Valnes LM,
   3. Dale AM, et al

   . Brain-wide glymphatic enhancement and clearance in humans assessed with MRI. JCI Insight 2018;3:121537 doi:10.1172/jci.insight.121537 pmid:29997300

   CrossRefPubMed
4. 4.↵
   1. Benveniste H,
   2. Lee H,
   3. Ozturk B, et al

   . Glymphatic cerebrospinal fluid and solute transport quantified by MRI and PET imaging. Neuroscience 2021;474:63–79 doi:10.1016/j.neuroscience.2020.11.014 pmid:33248153

   CrossRefPubMed
5. 5.↵
   1. Klostranec JM,
   2. Vucevic D,
   3. Bhatia KD, et al

   . Current concepts in intracranial interstitial fluid transport and the glymphatic system, Part II: imaging techniques and clinical applications. Radiology 2021;301:516–32 doi:10.1148/radiol.2021204088 pmid:34698564

   CrossRefPubMed
6. 6.↵
   1. Mallio CA,
   2. Rovira À,
   3. Parizel PM, et al

   . Exposure to gadolinium and neurotoxicity: current status of preclinical and clinical studies. Neuroradiology 2020;62;925–34 doi:10.1007/s00234-020-02434-8 pmid:32318773

   CrossRefPubMed
7. 7.↵
   1. Patel M,
   2. Atyani A,
   3. Salameh JP, et al

   . Safety of intrathecal administration of gadolinium-based contrast agents: a systematic review and meta-analysis. Radiology 2020;297:75–83 doi:10.1148/radiol.2020191373 pmid:32720867

   CrossRefPubMed
8. 8.↵
   1. Halvorsen M,
   2. Edeklev CS,
   3. Fraser-Green J, et al

   . Off-label intrathecal use of gadobutrol: safety study and comparison of administration protocols. Neuroradiology 2021;63:51–61 doi:10.1007/s00234-020-02519-4 pmid:32803338

   CrossRefPubMed
9. 9.↵
   1. Edeklev CS,
   2. Halvorsen M,
   3. Lovland G, et al

   . Intrathecal use of gadobutrol for glymphatic MR imaging: prospective safety study of 100 patients. AJNR Am J Neuroradiol 2019;40:1257–64 doi:10.3174/ajnr.A6136 pmid:31320462

   Abstract/FREE Full Text
10. 10.↵
    1. Eide PK,
    2. Pripp AH,
    3. Ringstad G

    . Magnetic resonance imaging biomarkers of cerebrospinal fluid tracer dynamics in idiopathic normal pressure hydrocephalus. Brain Commun 2020;2:faa187 doi:10.1093/braincomms/fcaa187 pmid:33381757

    CrossRefPubMed
11. 11.↵
    1. Eide PK,
    2. Lashkarivand A,
    3. Hagen-Kersten ÅA, et al

    . Intrathecal contrast-enhanced magnetic resonance imaging of cerebrospinal fluid dynamics and glymphatic enhancement in idiopathic normal pressure hydrocephalus. Front Neurol 2022;13:857328 doi:10.3389/fneur.2022.857328 pmid:35463139

    CrossRefPubMed
12. 12.↵
    1. Kanal E

    . A reality check on intrathecal gadolinium-based contrast agents. Radiology 2020;297:84–86 doi:10.1148/radiol.2020202819 pmid:32726195

    CrossRefPubMed
13. 13.↵
    1. Ringstad G,
    2. Eide PK

    . Safety of intrathecal gadolinium-based contrast agents and benefit versus risk. Radiology 2021;299:E223–24 doi:10.1148/radiol.2021203351 pmid:33591893

    CrossRefPubMed
14. 14.↵
    1. Nath S,
    2. Koziarz A,
    3. Badhiwala JH, et al

    . Atraumatic versus conventional lumbar puncture needles: a systematic review and meta-analysis. Lancet 2018;391:1197–20 doi:10.1016/S0140-6736(17)32451-0 pmid:29223694

    CrossRefPubMed
15. 15.↵
    1. Akbar JJ,
    2. Luetmer PH,
    3. Schwartz KM, et al

    . The role of MR myelography with intrathecal gadolinium in localization of spinal CSF leaks in patients with spontaneous intracranial hypotension. AJNR Am J Neuroradiol 2012;33:535–40 doi:10.3174/ajnr.A2815 pmid:22173753

    Abstract/FREE Full Text
16. 16.↵
    1. Selcuk H,
    2. Albayram S,
    3. Ozer H, et al

    . Intrathecal gadolinium-enhanced MR cisternography in the evaluation of CSF leakage. AJNR Am J Neuroradiol 2010;31:71–75 doi:10.3174/ajnr.A1788 pmid:19762462

    Abstract/FREE Full Text
17. 17.↵
    1. Eide PK,
    2. Pripp AH,
    3. Ringstad G, et al

    . Impaired glymphatic function in idiopathic intracranial hypertension. Brain Commun 2021;3:fcab04 doi:10.1093/braincomms/fcab043 pmid:34235434

    CrossRefPubMed
18. 18.↵
    1. Eide PK,
    2. Pripp AH,
    3. Berge B, et al

    . Altered glymphatic enhancement of cerebrospinal fluid tracer in individuals with chronic poor sleep quality. J Cereb Blood Flow Metab 2022;42:1676–96 doi:10.1177/0271678X221090747 pmid:35350917

    CrossRefPubMed
19. 19.↵
    1. Hovd MH,
    2. Mariussen E,
    3. Uggerud H, et al

    . Population pharmacokinetic modeling of CSF to blood clearance: prospective tracer study of 161 patients under work-up for CSF disorders. Fluids Barriers CNS 2022;19:55 doi:10.1186/s12987-022-00352-w pmid:35778719

    CrossRefPubMed
20. 20.↵
    1. Tamargo J,
    2. Heuzey L,
    3. Mabo JY

    . Narrow therapeutic index drugs: a clinical pharmacological consideration to flecainide. Eur J Clin Pharmacol 2015;71:549–67 doi:10.1007/s00228-015-1832-0 pmid:25870032

    CrossRefPubMed
21. 21.↵
    1. Nehra AK,
    2. McDonald RJ,
    3. Bluhm AM, et al

    . Accumulation of gadolinium in human cerebrospinal fluid after gadobutrol-enhanced MR imaging: a prospective observational cohort study. Radiology 2018;288:416–23 doi:10.1148/radiol.2018171105 pmid:29737947

    CrossRefPubMed
22. 22.↵
    1. Berger F,
    2. Kubik-Huch RA,
    3. Niemann T, et al

    . Gadolinium distribution in cerebrospinal fluid after administration of a gadolinium-based MR contrast agent in humans. Radiology 2018;288:703–09 doi:10.1148/radiol.2018171829 pmid:29737953

    CrossRefPubMed
23. 23.↵
    1. Cao D,
    2. Kang N,
    3. Pillai JJ, et al

    . Fast whole brain MR imaging of dynamic susceptibility contrast changes in the cerebrospinal fluid (cDSC MRI). Magn Reson Med 2020;84:3256–70 doi:10.1002/mrm.28389 pmid:32621291

    CrossRefPubMed
24. 24.↵
    1. Jost G,
    2. Frenzel T,
    3. Lohrke J, et al

    . Penetration and distribution of gadolinium-based contrast agents into the cerebrospinal fluid in healthy rats: a potential pathway of entry into the brain tissue. Eur Radiol 2017;27:2877–85 doi:10.1007/s00330-016-4654-2 pmid:27832312

    CrossRefPubMed
25. 25.↵
    1. Deike-Hofmann K,
    2. Reuter J,
    3. Haase R, et al

    . Glymphatic pathway of gadolinium-based contrast agents through the brain: overlooked and misinterpreted. Invest Radiol 2019;54:229–37 doi:10.1097/RLI.0000000000000533 pmid:30480554

    CrossRefPubMed
26. 26.↵
    1. Naganawa S,
    2. Ito R,
    3. Kawai H, et al

    . Confirmation of age-dependence in the leakage of contrast medium around the cortical veins into cerebrospinal fluid after intravenous administration of gadolinium-based contrast agent. Magnetic Reson Med 2020;19:375–81 doi:10.2463/mrms.mp.2019-0182 pmid:32023561

    CrossRefPubMed
27. 27.↵
    1. Green C,
    2. Jost G,
    3. Frenzel T, et al

    . The effect of gadolinium-based contrast agents on longitudinal changes of magnetic resonance imaging signal intensities and relaxation times in the aging rat brain. Invest Radiol 2022;57:453–62 doi:10.1097/RLI.0000000000000857 pmid:35125411

    CrossRefPubMed
28. 28.↵
    1. Kobayashi M,
    2. Levendovszky SR,
    3. Hippe DS, et al

    . Comparison of human tissue gadolinium retention and elimination between gadoteridol and gadobenate. Radiology 2021;300:559–69 doi:10.1148/radiol.2021204320 pmid:34128720

    CrossRefPubMed